<DOC>
	<DOCNO>NCT02693340</DOCNO>
	<brief_summary>This monocentric prospective study collection biological sample ( blood biopsy ) use vitro biomarker assay ( ) perform identify predictive marker response biological treatment inflammatory bowel disease ( IBD ) .</brief_summary>
	<brief_title>Evolution Lymphocyte Populations Under Biotherapy Inflammatory Bowel Disease</brief_title>
	<detailed_description />
	<mesh_term>Intestinal Diseases</mesh_term>
	<mesh_term>Inflammatory Bowel Diseases</mesh_term>
	<criteria>Patients age 18 . Crohn 's Disease Diagnosis ( CD ) ulcerative colitis ( UC ) accord define criterion ( ECCO recommendation ) . Active disease define clinical biological and/or morphological assessment . Initiation antiTumor Necrosis Factor ( TNF ) therapy ( Infliximab , Adalimumab , Golimumab ) new biotherapy ( Vedolizumab , Ustekinumab ) provide connection management digestive disease . Patient ( e ) sign date consent study undertaking procedure relate study . Patients guardianship / curator Following Situations Persons unable understand , read / sign inform consent Patient follow function : investigator coinvestigator , research assistant , pharmacist , study coordinator involvement study Uncooperative person potentially noncompliant study procedure predictable difficulty regular monitoring 1 year . No affiliation social security scheme , universal medical coverage similar plan . Pregnant lactating woman .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>